Date:10/29/2009

edged instrument are recognized in earnings. As a result, we recognized a gain of approximately $10.9 million and $19.6 million for the quarter and nine months ended September 30, 2009, respectively, which is reflected within non-operating income in our consolidated statement of earnings. Additionally in the third quarter of 2009, we recorded a $2.2 million foreign currency gain related to the days between obtaining the funds (denominated in Yen) and remitting the funds to purchase ODS. Furthermore, we recorded an exchange gain of $4.9 million on settlement of intercompany loans related to the funding of the ODS acquisition in the quarter ended September 30, 2009. c) Fair market value inventory adjustment - We recorded an $8.8 million charge during the third quarter of 2009 related to the fair value of acquired inventory in connection with the ODS acquisition, as a portion of the acquired inventory was sold during the third quarter. A similar charge for $1.0 million was incurred during the first quarter of 2008 in connection with our acquisition of the flow cytometry business of Dako A/S related to the fair value of acquired inventory sold in the first quarter. d) Inventory write-off - We recorded a charge of $1.6 million related to inventory written off due to discontinuation of certain product lines in the third quarter of 2009. e) Interest expense on debt offering - On May 26, 2009, we issued $250 million principal amount of the Company's 6% Senior Notes due 2015 and $250 million principal amount of the Company's 7% Senior Notes due 2019 (the "Notes"). The proceeds from the Notes were used to partially fund the ODS acquisition. During the third quarter and nine months ended September 30, 2009, we incurred approximately $2.4 million and $5.6 milli
'/>"/>

SOURCE Beckman Coulter, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results